Clinical Trial Update: Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Pediatric Cancer | Phase 2 | Status: COMPLETED